Biocon Acquires ₹315.34 Million OCRPS In Biosphere Unit, Injects ₹2 Billion Into Pharma Subsidiary

Biocon Limited has acquired Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS) in two wholly owned subsidiaries, a move aimed at funding internal working capital and capital expenditure requirements.

The disclosure, submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on March 3, 2026 states that the investments were completed on the same day through allotment of preference shares by Biocon Biosphere Limited (BBSL) and Biocon Pharma Limited (BPL).

Capital Infusion Through OCRPS Allotments

According to the filing reference BIO/SECL/TG/2025-26/184 dated March 3, 2026, the company acquired:

• 11,53,44,285 OCRPS of ₹10 each issued by Biocon Biosphere Limited
• 20,00,00,000 OCRPS of ₹10 each issued by Biocon Pharma Limited

The transaction value differs for the two subsidiaries.

For Biocon Biosphere Limited, the total consideration amounts to ₹1,15,34,42,850, consisting of ₹20,00,00,000 in cash and ₹93,10,00,000 representing earlier loans extended to the subsidiary along with accrued interest aggregating ₹95,34,42,850, which have been adjusted as part of the subscription.

For Biocon Pharma Limited, the investment was made through cash consideration of ₹2,00,00,00,000.

Each preference share carries a face value of ₹10 and was issued at par, according to the annexure to the regulatory disclosure.

Technical note: OCRPS are hybrid securities that function as preference shares but include a conversion option into equity. They typically provide capital support while preserving structural flexibility for the parent entity.

Share Price Reaction

Shares of Biocon Limited traded lower during Tuesday’s session.

The stock was ₹377.85, down ₹10.10 or 2.60%, as of 1:48 PM IST on March 4, 2026, according to exchange data. The session saw the shares fluctuate between ₹376.05 and ₹385.60 so far, compared with the previous close of ₹387.95.

The company’s market capitalisation stood at approximately ₹61,190 crore at the time of the intraday snapshot.

Subsidiary Background

Both investee entities are wholly owned subsidiaries, meaning the parent already controls 100% of the paid-up equity share capital, with the preference allotments representing internal funding rather than an acquisition of external assets.

Biocon Biosphere Limited, incorporated on December 24, 2019, is engaged in pharmaceutical manufacturing, including APIs and generic formulations, with facilities in Vizag and Bengaluru.
The unit reported turnover of ₹130 million for FY2024-25, following ₹6 million in FY2023-24 and nil revenue in FY2022-23, according to the filing.

Biocon Pharma Limited, incorporated on October 31, 2014, develops and manufactures generic formulations for global markets, including the United States and Europe. The subsidiary reported turnover of ₹9,825 million in FY2024-25, up from ₹8,816 million in FY2023-24 and ₹6,232 million in FY2022-23.

Because the transactions occur between a listed holding company and its wholly owned subsidiaries, they fall within the related-party transaction framework but remain exempt under Regulation 23(5) of SEBI’s Listing Regulations, which excludes intra-group dealings of this nature.

No governmental or regulatory approvals were required for the allotments.

Internal Funding Rather Than Expansion

The filing frames the investment as internal capital allocation rather than an external acquisition.

The funds are intended to support ongoing business requirements, including working capital, capital expenditure and general corporate needs at the subsidiary level.

In practical terms, the move consolidates financing within the group structure preference capital replacing part of the loan exposure while maintaining Biocon’s full ownership of both operating units.

Source: https://nsearchives.nseindia.com/corporate/Bioconlimited_03032026230815_SE_Intimation_-_Acquisition_BPL_BBSL_v3_signed.pdf